Literature DB >> 20019078

Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants.

Oana Ciofu1, Lotte F Mandsberg1, Thomas Bjarnsholt2,1, Tina Wassermann1, Niels Høiby2,1.   

Abstract

During the chronic lung infection of patients with cystic fibrosis (CF), Pseudomonas aeruginosa can survive for long periods due to adaptive evolution mediated by genetic variation. Hypermutability is considered to play an important role in this adaptive evolution and it has been demonstrated that mutator populations are amplified in the CF lung by hitchhiking with adaptive mutations. Two of the genes that are frequently mutated in isolates from chronic infection are mucA and lasR. Loss-of-function mutations in these genes determine the phenotypic switch to mucoidy and loss of quorum sensing, which are considered hallmarks of chronic virulence. The aims of our study were to investigate (1) the genetic background of the P. aeruginosa subpopulations with non-mutator, weak or strong mutator phenotype and their dynamics during the chronic lung infection, and (2) the time sequence in which the hypermutable, mucoid and quorum-sensing-negative phenotypes emerge during chronic lung infection. For these purposes the sequences of mutS, mutL, uvrD, mutT, mutY and mutM anti-mutator genes as well as of mucA and lasR were analysed in 70 sequential P. aeruginosa isolates obtained from the respiratory secretions of 10 CF patients (one to three isolates per time point). Analysis of the genetic background of the mutator phenotype showed that mutS was the most commonly affected gene followed by mutL in isolates with strong mutator phenotype. The mutT, mutY, mutM genes were affected in isolates with low fold-changes in the mutation frequencies compared to the reference strain PAO1. Isolates with non-mutator, weak or strong mutator phenotype were represented at all time points showing co-existence of these subpopulations, which suggests parallel evolution of the various mutators in the different focal niches of infection in the CF lung. Mutations in mucA and lasR occurred earlier than mutations in the anti-mutator genes, showing that hypermutability is not a prerequisite for the acquisition of mucoidy and loss of quorum sensing, considered hallmarks of chronic virulence. Significantly higher mutation rates and MICs of ceftazidime, meropenem and ciprofloxacin were found for isolates collected late (more than 10 years) during the chronic lung infection compared to isolates collected earlier, which suggests an amplification of the mutator subpopulation by hitchhiking with development of antibiotic resistance. Similar evolutionary pathways concordant with adaptive radiation were observed in different clonal lineages of P. aeruginosa from CF patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20019078     DOI: 10.1099/mic.0.033993-0

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  76 in total

1.  Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections.

Authors:  Ashley E Warren; Carla M Boulianne-Larsen; Christine B Chandler; Kami Chiotti; Evgueny Kroll; Scott R Miller; Francois Taddei; Isabelle Sermet-Gaudelus; Agnes Ferroni; Kathleen McInnerney; Michael J Franklin; Frank Rosenzweig
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Emergence of a mutL mutation causing multilocus sequence typing-pulsed-field gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient.

Authors:  María García-Castillo; Luis Máiz; María-Isabel Morosini; Mercedes Rodríguez-Baños; Lucrecia Suarez; Ana Fernández-Olmos; Fernando Baquero; Rafael Cantón; Rosa del Campo
Journal:  J Clin Microbiol       Date:  2012-02-08       Impact factor: 5.948

3.  Biological markers of Pseudomonas aeruginosa epidemic high-risk clones.

Authors:  Xavier Mulet; Gabriel Cabot; Alain A Ocampo-Sosa; M Angeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 4.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

Review 5.  Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator.

Authors:  Deepak Balasubramanian; Hansi Kumari; Kalai Mathee
Journal:  Pathog Dis       Date:  2015-02-26       Impact factor: 3.166

Review 6.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 7.  Hypermutation and stress adaptation in bacteria.

Authors:  R Jayaraman
Journal:  J Genet       Date:  2011-08       Impact factor: 1.166

8.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 9.  Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives.

Authors:  Daniel J Hassett; Michael T Borchers; Ralph J Panos
Journal:  J Microbiol       Date:  2014-03-01       Impact factor: 3.422

10.  Epoxide-mediated CifR repression of cif gene expression utilizes two binding sites in Pseudomonas aeruginosa.

Authors:  Alicia E Ballok; Christopher D Bahl; Emily L Dolben; Allia K Lindsay; Jessica D St Laurent; Deborah A Hogan; Dean R Madden; George A O'Toole
Journal:  J Bacteriol       Date:  2012-07-27       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.